Binbing Yu
Overview
Explore the profile of Binbing Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baria K, De Toni E, Yu B, Jiang Z, Kabadi S, Malvezzi M
Gastro Hep Adv
. 2024 Aug;
1(4):618-626.
PMID: 39132071
Background And Aims: Biliary tract cancer (BTC) consists of a group of hepatic and perihepatic tumors that are in close proximity but are anatomically different, including gallbladder cancer (GBC), cholangiocarcinoma...
2.
Wang J, Yu B, Dou Y, Mascaro J
JCO Precis Oncol
. 2024 Jun;
8:e2400116.
PMID: 38848518
In oncology drug development, using biomarkers to select a study population more likely to benefit from a therapeutic effect is critical to increase the efficiency of a clinical trial in...
3.
Koshiol J, Yu B, Kabadi S, Baria K, Shroff R
BMC Cancer
. 2022 Nov;
22(1):1178.
PMID: 36384474
Background: Biliary tract cancer (BTC) includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer (AVC). Although BTC is rare in the US, incidence is increasing and...
4.
Broglio K, Marshall J, Yu B, Frewer P
Ther Innov Regul Sci
. 2022 Jan;
56(2):291-300.
PMID: 34988927
Introduction: Simon's design has been widely used in oncology to conduct single arm phase II trials and to make Go/No-Go development decision. Other authors have proposed designs with decision-making frameworks...
5.
Casey K, Smith M, Sinibaldi D, Seto N, Playford M, Wang X, et al.
Arthritis Rheumatol
. 2020 Sep;
73(3):459-471.
PMID: 32909675
Objective: Neutrophil dysregulation and the type I interferon (IFN) axis have been proposed to contribute to premature cardiovascular disease, a leading cause of mortality in patients with systemic lupus erythematosus...
6.
Sondag P, Zeng L, Yu B, Yang H, Novick S
Pharm Stat
. 2019 Nov;
19(3):230-242.
PMID: 31762118
Potency bioassays are used to measure biological activity. Consequently, potency is considered a critical quality attribute in manufacturing. Relative potency is measured by comparing the concentration-response curves of a manufactured...
7.
Yu B, Yang H, Sabin A
Contemp Clin Trials Commun
. 2019 Oct;
16:100454.
PMID: 31650074
The goal of a non-inferiority trial is to evaluate whether the effect of an experimental treatment is not inferior to that of the active control. Determination of an appropriate non-inferiority...
8.
Zhao W, Vicini P, Novick S, Anderton J, Davies G, DAngelo G, et al.
Pharm Stat
. 2019 May;
18(6):688-699.
PMID: 31140720
Linear models are generally reliable methods for analyzing tumor growth in vivo, with drug effectiveness being represented by the steepness of the regression slope. With immunotherapy, however, not all tumor...
9.
Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
Chia Y, Yan L, Yu B, Wang B, Barker P, Goldman M, et al.
Clin Pharmacol Ther
. 2019 Jan;
106(2):383-390.
PMID: 30661249
We evaluated the relationship between benralizumab (30 mg every 4 and 8 weeks (Q4W, Q8W)) pharmacokinetic (PK) exposure and end points of asthma exacerbation rates (AERs) and change from baseline...
10.
Sondag P, Zeng L, Yu B, Rousseau R, Boulanger B, Yang H, et al.
Pharm Stat
. 2018 Aug;
17(6):701-709.
PMID: 30112804
The USP<1032> guidelines recommend the screening of bioassay data for outliers prior to performing a relative potency (RP) analysis. The guidelines, however, do not offer advice on the size or...